Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 178

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 178
---
 any equity ownership guidelines
for our executives, which is consistent with other pre-commercial biotechnology companies that use stock options as the long-term incentive
vehicle. Further, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership
culture and help to align the interests of our executives and our stockholders. In addition, the vesting feature of our equity awards
contributes to executive retention by providing an incentive for our executives to remain in our employment during the vesting period.
We expect that our Board will continue to use annual equity awards to compensate our executive officers. We may also make additional discretionary
grants, typically in connection with the promotion of an employee, to reward an employee, for retention purposes or in other circumstances
as the Board deems appropriate.

Employment/Consulting Agreements

Amir Avraham. On May 22, 2025, Mr.
Avraham was appointed as interim Chief Executive Officer. Prior to his appointment as interim Chief Executive Officer, Mr. Avraham provided
to us general consulting servies pursuant to a consulting agreement entered into with our subsidiary Revium RX Ltd. on February 26, 2024,
as subsequently amended as of May 22, 2025. Under the original consulting agreement, Mr. Avraham was paid a monthly fee of 15,000 NIS,
which as of May 22, 2025 upon his appointment as CEO, the monthly fee under the consulting agreement was increased to 30,000 NIS, pending
the negotiation and execution of a new agreement reflecting new compensation terms which as of the date of this prospectus have not been
agreed to. Either we or Mr. Avraham is entitled to terminate the agreement and the services thereunder at any time and for many reason
upon 30 days’ notice. Under the consulting agreement, Mr. Avraham also undertook that during the term of the consulting agreement
and for a 12 month period thereafter he would not compete with the Company.

The consulting agreement contain customary
confidentiality obligations which are not limited by the term of the agreement.

Inna Martin. The Company’s subsidiary
Revium RX Ltd. entered into Consultancy Agreement with Ms. Martin (the “Consulting Agreement”) on December 15, 2020, as subsequently
amended, setting forth the terms of her compensation. Under the Consulting Agreement, Ms. Martin was entitled through July 2023 to a monthly
fee of the current New Israeli